Heparin Bridging After Withholding Antiplatelets in Urological Surgery
Heparin bridging is generally discouraged after stopping antiplatelet therapy for urological surgery, as bridging increases bleeding risk without reducing thrombotic complications in most patients. The evidence consistently shows that bridging with low molecular weight heparin (LMWH) leads to more bleeding complications than continuing antiplatelet therapy or simple interruption without bridging 1, 2, 3.
Key Recommendations by Clinical Scenario
For Patients on Aspirin Alone
- Continue aspirin perioperatively for most urological procedures 1
- Low-dose aspirin does not significantly increase major bleeding risk and can be safely continued
- The thrombotic risks of aspirin cessation generally outweigh minor bleeding risks for the majority of procedures 1
For Patients on Dual Antiplatelet Therapy (DAPT)
Critical timing considerations:
- Within 1 month of any coronary stent: Only perform lifesaving procedures; continue both aspirin and clopidogrel 1, 4
- Within 12 months of drug-eluting stent: Continue both agents perioperatively 5
- Within 6 weeks of bare metal stent: Continue both agents perioperatively 5
Bridging with other anticoagulants or IV antiplatelet medications is poorly studied and discouraged 1
When Bridging May Be Considered (Anticoagulation, NOT Antiplatelets)
The guidelines address bridging primarily for patients on anticoagulants (warfarin, not antiplatelets). If a patient requires both anticoagulation AND antiplatelet therapy:
High thromboembolic risk patients only:
- Mechanical heart valves
- Recent venous thromboembolism
- Atrial fibrillation with high stroke risk
Bridging protocol if indicated 1, 6:
Pre-operative:
- Start LMWH 36-48 hours after last warfarin dose (3 days preoperatively)
- Stop LMWH 24 hours before surgery (not 12 hours, to minimize residual anticoagulant effect) 6
- For unfractionated heparin (UFH): stop ≥4 hours before surgery 6
Post-operative:
- Resume LMWH ≥24 hours after surgery or until bleeding has almost completely subsided 1, 6
- For UFH: resume ≥24 hours post-operatively without bolus dose, using lower-intensity infusion 6
- Continue bridging until warfarin reaches therapeutic INR on 2 separate measurements 1
Evidence-Based Cautions
Bleeding Risk with Bridging
Recent prospective data shows LMWH bridging in urological surgery significantly increases 3:
- Transfusion rates (2.27% vs 0%, p=0.038)
- Postoperative clot retention (7.57% vs 0.53%, p=0.008)
- Re-catheterization (9.09% vs 3.72%, p=0.046)
- Re-admission for hematuria (11.36% vs 3.72%, p=0.008)
The RECO Study Warning
The landmark RECO study demonstrated that interruption of aspirin perioperatively in high-risk cardiac patients was associated with increased cardiac complications due to platelet rebound and hypercoagulable state 1. This emphasizes continuing aspirin rather than bridging with heparin.
Common Pitfalls to Avoid
- Do not bridge patients who only need antiplatelet therapy - this increases bleeding without benefit
- Do not stop aspirin in patients with recent stents - thrombotic risk far exceeds bleeding risk
- Do not give LMWH within 24 hours of surgery - residual anticoagulant effect increases bleeding 6
- Do not resume therapeutic anticoagulation too early post-operatively - wait until hemostasis is secure 1, 6
Algorithm for Decision-Making
Step 1: Identify the medication
- Aspirin alone → Continue perioperatively
- DAPT with recent stent → Continue both agents
- DAPT without recent stent → Consider stopping P2Y12 inhibitor only, continue aspirin
Step 2: If anticoagulation (not just antiplatelet) must be stopped
- Assess thromboembolic risk (high/moderate/low)
- Only bridge if HIGH thromboembolic risk
- Use LMWH (or UFH if CrCl <30 mL/min)
Step 3: Timing
- Stop LMWH 24 hours pre-op
- Resume LMWH ≥24 hours post-op when hemostasis secure